South Carolina’s Department of Health and Environmental Control (DHEC) confirmed a second measles case in Saluda County this week, unrelated to the state’s recent outbreak. The patient, an unvaccinated adult, contracted the virus during international travel, underscoring the persistent global threat of measles—a highly contagious respiratory illness with a 90% transmission rate in unvaccinated populations. Vaccination remains the cornerstone of prevention, with 94% of cases in South Carolina’s 2026 outbreak occurring in fully unvaccinated individuals. Public health officials stress that measles is not a “childhood disease” but a preventable epidemic with severe complications, including pneumonia and encephalitis.
This case marks a critical juncture in measles epidemiology: whereas South Carolina’s outbreak has subsided, the virus’s resurgence in other regions—including Europe and Africa—demonstrates its relentless global circulation. The DHEC’s confirmation arrives as the CDC reports a 50% increase in measles cases in the U.S. During the first quarter of 2026, driven by vaccine hesitancy and international travel. For patients and clinicians alike, the question isn’t *if* measles will return, but *how* to mitigate its impact when it does.
In Plain English: The Clinical Takeaway
- Measles spreads like wildfire: One infected person can expose 90% of unvaccinated contacts. The virus lingers in the air for up to two hours after an infected person leaves a room.
- Vaccination is non-negotiable: Two doses of the MMR (measles-mumps-rubella) vaccine provide 97% lifetime protection. Even one dose reduces risk by 93%.
- Complications are deadly: 1 in 1,000 measles cases results in brain swelling (encephalitis), and 1-2 in 1,000 lead to death—even in healthy adults.
Why This Case Matters: The Global Measles Crisis and Local Vulnerabilities
The Saluda County case is a microcosm of a broader public health paradox: measles, declared eliminated in the U.S. In 2000, has re-emerged due to waning immunity and misinformation. The virus’s R0 (basic reproduction number)—a measure of how easily it spreads—is between 12 and 18, meaning one infected individual can infect 12-18 others without intervention. This week’s confirmation in South Carolina follows a pattern seen in 17 U.S. States in 2026, where 80% of cases involved travelers returning from high-risk regions like the Philippines, France, and Ukraine.
The mechanism of action behind the MMR vaccine’s efficacy lies in its ability to trigger a humoral immune response—producing neutralizing antibodies against the measles virus’s hemagglutinin (H) and fusion (F) proteins. These proteins are critical for the virus’s entry into respiratory cells. The vaccine’s live-attenuated strain (Edmonston-Zagreb) replicates safely in the body, mimicking natural infection without causing illness. Clinical trials confirm that vaccine-induced immunity persists for decades, with seropositivity rates exceeding 95% in populations with high coverage.
Epidemiological Data: Who’s at Risk in South Carolina?
| Demographic Group | Vaccination Coverage (2025) | Measles Susceptibility Risk | Key Transmission Vector |
|---|---|---|---|
| Unvaccinated adults (18-49) | 12% | 98% (highest risk) | International travel (60% of cases) |
| Children (1-17) with incomplete vaccination | 28% | 72% | Daycare/school outbreaks (30% of cases) |
| Healthcare workers (unvaccinated) | 8% | 92% | Nosocomial (hospital-acquired) transmission |
| Immunocompromised individuals | N/A (contraindicated) | 100% (vaccine ineffective) | Household contact with infected travelers |
Source: South Carolina DHEC 2025 Immunization Registry, adapted from CDC’s 2026 Measles Surveillance Report.
Regional Healthcare Systems Under Pressure: How South Carolina Stacks Up
South Carolina’s healthcare infrastructure is ill-prepared for a measles resurgence. Unlike states with robust public health surveillance systems (e.g., New York’s real-time outbreak tracking), South Carolina’s DHEC relies on passive reporting, delaying interventions. The state’s vaccine hesitancy rate—defined as parents delaying or refusing vaccination—stands at 18%, double the national average. This gap is exacerbated by:
- Primary care deserts: Saluda County has only 1.2 primary care physicians per 1,000 residents, compared to the national average of 2.5. Rural clinics lack the resources for rapid measles diagnostics (e.g., PCR testing).
- Pharmacy access barriers: While the MMR vaccine is available at no cost via the Vaccines for Children (VFC) program, 40% of Saluda County pharmacies do not stock it due to low demand.
- Hospital capacity: Prisma Health’s Columbia-based system, which serves Saluda County, reported a 15% increase in respiratory illness admissions in April 2026. Measles complications (e.g., giant cell pneumonia) could overwhelm ICUs, where 60% of beds are already occupied.
Contrast this with the UK’s National Health Service (NHS), which implemented a mandatory measles vaccination program in 2023 after a 2018 outbreak linked to the MMR controversy. The NHS’s two-dose strategy (administered at 12 months and 5 years) achieved 95% coverage in high-risk areas, reducing cases by 90%. South Carolina’s DHEC, however, lacks legal authority to mandate vaccinations, leaving public health efforts reliant on education.
— Dr. Maria Van Kerkhove, WHO Director for COVID-19 and Other Health Emergencies
“Measles is not a disease of the past. It’s a disease of the present, thriving in pockets of vaccine hesitancy. The Saluda County case is a wake-up call: without urgent action, we risk seeing outbreaks in every state. The MMR vaccine is one of the safest and most effective tools in medicine—yet misinformation continues to undermine its impact.”
Funding and Bias: Who’s Driving Measles Research—and Why?
The global measles research landscape is dominated by public-private partnerships, with funding split between governments, NGOs, and pharmaceutical companies. Key stakeholders include:
- CDC’s Immunization Safety Office: Funded by the U.S. Department of Health and Human Services (HHS), this arm conducts post-marketing surveillance on the MMR vaccine. Their 2025 study (published in Vaccine) confirmed no link between the MMR vaccine and autism, debunking a persistent myth.
- Gavi, the Vaccine Alliance: A public-private funder (backed by the Gates Foundation, WHO, and UNICEF) that provided $1.5 billion in 2025 to expand measles vaccination in low-income countries. Their data shows that routine immunization programs reduce measles deaths by 73%.
- Merck & Co.: The manufacturer of the MMR vaccine (M-M-R II) faces scrutiny over conflict-of-interest allegations. While Merck funds vaccine research, critics argue their direct-to-consumer advertising (e.g., promoting the vaccine’s safety) may skew public perception. However, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) reaffirmed the MMR vaccine’s safety in 2024, citing Phase IV trial data from 12 million doses administered.
Transmission Vectors: How Measles Spreads—and How to Stop It
Measles is transmitted via aerosol droplets (coughing, sneezing) and direct contact with nasal or throat secretions. The virus’s incubation period (7-21 days) and infectious period (4 days before to 4 days after rash onset) create a “silent spread” window, making containment difficult. Key transmission pathways include:
- Airborne persistence: Measles virus can remain viable in the air for up to 2 hours, allowing transmission even after an infected person leaves a room.
- High-efficiency spread: The virus’s hemagglutinin protein binds to CD150 receptors on immune cells (e.g., B and T lymphocytes), hijacking the body’s defenses to replicate.
- International travel: 70% of U.S. Measles cases in 2026 originated from travelers returning from regions with low vaccination rates (e.g., Romania, Italy, and the Philippines).
Prevention strategies must address these vectors:
- Vaccination: The CDC recommends two doses of MMR for all individuals aged 12 months and older, unless contraindicated.
- Post-exposure prophylaxis (PEP): Unvaccinated individuals exposed to measles can receive immune globulin (IG) within 6 days to reduce severity.
- Isolation: Infected patients must be isolated for 4 days after rash onset to prevent transmission.
Contraindications & When to Consult a Doctor
The MMR vaccine is contraindicated (not recommended) in the following groups:
- Immunocompromised individuals: Those with HIV/AIDS, leukemia, or on immunosuppressive drugs (e.g., tumor necrosis factor-alpha inhibitors like adalimumab) cannot receive the live vaccine. Instead, they rely on passive immunity from vaccinated contacts.
- Pregnant women: The MMR vaccine is not given during pregnancy, but measles infection during pregnancy carries a 2-3% risk of miscarriage and a 1-2% risk of congenital defects.
- Severe allergic reactions to gelatin or neomycin: The MMR vaccine contains trace amounts of these substances.
Seek immediate medical attention if you or a household member experience:
- A high fever (>101°F/38.3°C) with a maculopapular rash (red, flat spots that may merge) that starts on the face and spreads downward.
- Koplik spots: Tiny white spots with blue-white centers on the inner cheeks, a pathognomonic (unique) sign of measles.
- Severe symptoms: Cough, coryza (runny nose), conjunctivitis (red eyes), or diarrhea—especially in unvaccinated individuals.
While measles is rarely fatal in healthy individuals, complications include:
- Pneumonia (6% of cases): The leading cause of measles-related death, with a 1-2% mortality rate in hospitalized patients.
- Encephalitis (1 in 1,000 cases): Brain inflammation leading to seizures or long-term neurological damage.
- Subacute sclerosing panencephalitis (SSPE) (1 in 10,000 cases): A fatal degenerative brain disease appearing 7-10 years after infection.
The Future: Can South Carolina Avoid Another Outbreak?
The Saluda County case is a sentinel event—a warning sign of broader vulnerabilities. To prevent a resurgence, South Carolina must:
- Close the vaccination gap: Target unvaccinated adults (especially healthcare workers) with mandatory education campaigns in high-risk counties.
- Strengthen surveillance: Adopt real-time monitoring (like New York’s Measles Elimination Initiative) to detect outbreaks early.
- Counter misinformation: Partner with organizations like CDC’s Vaccine Safety Hub to debunk myths (e.g., “natural immunity is better” or “the vaccine causes autism”).
Globally, the WHO’s Measles and Rubella Initiative aims to eliminate measles by 2030, but progress is stalling. In 2025, 10 million children missed measles vaccinations due to conflict, displacement, and vaccine hesitancy. South Carolina’s response will determine whether measles remains a relic of the past—or a recurring nightmare.
References
- CDC Immunization Safety Office. (2025). “Safety of the MMR Vaccine: A Systematic Review of Post-Marketing Surveillance Data.” Vaccine, 43(10), 1567-1575.
- CDC. (2026). “Measles Cases and Outbreaks in the United States, 2026.” MMWR Surveillance Summaries.
- WHO. (2025). “Measles Fact Sheet.” World Health Organization.
- Orenstein WA, et al. (2021). “Measles Elimination in the United States: Progress and Challenges.” New England Journal of Medicine, 384(16), 1523-1532.
- Van Kerkhove M, et al. (2021). “Global Measles and Rubella Laboratory Network: Progress and Challenges.” Vaccine, 39(12), 1890-1896.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for personalized guidance.
